Beyond Amyloid Beta: A New Alzheimer Disease Biomarker?
An AAN Poster Brief
"Alzheimer's Disease" is already on your Topic Alert list.
Drug & Reference Information
Editor's Note:
This year's American Academy of Neurology Annual Meeting featured an Integrative Neuroscience Session looking at advances in, and the potential role of, biomarkers in Alzheimer disease (AD). Following the session, Medscape spoke with Jacques Hugon, MD, PhD, Professor of Neurology at Saint-Louis Lariboisière Fernand-Widal Hospital in Paris, France, about a biomarker with the potential to aid in AD diagnosis. It's not amyloid beta or tau.
This year's American Academy of Neurology Annual Meeting featured an Integrative Neuroscience Session looking at advances in, and the potential role of, biomarkers in Alzheimer disease (AD). Following the session, Medscape spoke with Jacques Hugon, MD, PhD, Professor of Neurology at Saint-Louis Lariboisière Fernand-Widal Hospital in Paris, France, about a biomarker with the potential to aid in AD diagnosis. It's not amyloid beta or tau.
Medscape: Dr. Hugon, what can you tell us about PKR?
No comments:
Post a Comment